New trial
Phase 3 Study of Ifinatamab Deruxtecan (B7-H3 ADC) Versus Docetaxel in mCRPC
- Trial ID
- NCT06925737 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Location
- 7 Locations
- Published in
- New in Oncology - June 6, 2025
Merck is sponsoring this open-label study comparing ifinatamab deruxtecan—a B7-H3–directed antibody-drug conjugate with a Topo1 inhibitor payload—with standard docetaxel plus prednisone in patients with mCRPC post-ADT progression or following bilateral orchiectomy.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18